The Phase II Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes; TSUBAKI Study
Status:
Completed
Trial end date:
2017-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and efficacy of RTA 402 in chronic kidney
disease (CKD) patients with type 2 diabetes in a double-blind, placebo-controlled study when
this compound is administered once daily for 16 weeks in an intrapatient dose escalation
design.
Phase:
Phase 2
Details
Lead Sponsor:
Kyowa Hakko Kirin Company, Limited Kyowa Kirin Co., Ltd.